HiberCell Launches With $60.75 Million Series A to Target Dormant Metastatic Cancer Cells

HiberCell, based in New York City, launched with a $60.75 million Series A funding. The funding was led by ARCH Venture Partners. Additional investors included Hillhouse Capital, 6 Dimensions Capital, Celgene Corporation, the NYC Life Sciences Fund, and other undisclosed investors. HiberCell focuses on tumor dormancy detection and treatments. Recurrence of cancer, which is the cause of many cancer deaths, is driven by dormant disseminated tumor cells (DTCs) that remain undetected in the body for long periods of time. HiberCell is working to develop first-in-class drugs that target DTCs that originate from solid and liquid tumors.
“HiberCell is the foundational tumor dormancy company,” stated Alan Rigby, co-founder, president, and chief scientific officer of the company. “We know that dormant disseminated tumor cells are critical drivers of cancer metastasis. In translating this biology into the clinic, our work will be focused on further defining the characteristic genetics and transcriptomics of dormant disseminated tumor cells and charting a course to leverage our dormancy targets to improve patient outcomes and survival. We believe that this approach provides a differentiated opportunity to change the paradigm of cancer treatment.”